Skip to content

Merck stops development of CCR5 inhibitor vicriviroc

HIV cure efforts severely underfunded, US activists report

Atazanavir for children approved in European Union

Myriad halts HIV maturation inhibitor drug programme

Microbicides: the quest for user-friendly formulations

New grants for HIV cure research

Avexa halts apricitabine development due to cash shortage

Once-daily Kaletra approved for some treatment-experienced adults

Protease inhibitor monotherapy in clinical practice: valid option for undetectable patients